ARS Pharmaceuticals (NASDAQ: SPRY) CCO files first insider report with no shares

Rhea-AI Filing Summary

ARS Pharmaceuticals, Inc. reported an initial insider ownership filing for executive Margaret Ekins Smith, who serves as Chief Commercial Officer. The Form 3 shows no reportable transactions and no holdings entries at the time of this filing.

Key Figures

Reported buy transactions: 0 Reported sell transactions: 0 Holding entries: 0 +1 more

4 metrics

Reported buy transactions 0 Buy transactions count in transaction summary

Reported sell transactions 0 Sell transactions count in transaction summary

Holding entries 0 Number of holdings entries reported in this Form 3

Net buy/sell shares 0 Net buy/sell share balance across all transactions

FAQ

What does the SPRY Form 3 filing for Margaret Ekins Smith represent?

It is an initial insider ownership report for Margaret Ekins Smith at ARS Pharmaceuticals, Inc. It identifies her as Chief Commercial Officer and records that there are currently no reportable transactions or holdings entries associated with her in this filing.

What position does Margaret Ekins Smith hold at ARS Pharmaceuticals (SPRY)?

Margaret Ekins Smith is reported as the Chief Commercial Officer of ARS Pharmaceuticals, Inc. in this Form 3. This indicates she is an officer of the company but not listed as a director or 10% beneficial owner in the filing data.

Were any SPRY share transactions reported in Margaret Ekins Smith’s Form 3?

No transactions were reported for SPRY in this Form 3. The transaction list is empty, and the transaction summary shows 0 buy, 0 sell, and 0 acquire or dispose transactions, with net buy/sell direction marked as neutral.

Does the SPRY Form 3 show any share holdings for Margaret Ekins Smith?

The filing shows no holdings entries for Margaret Ekins Smith. The transactions array is empty and the holdingEntries count in the transaction summary is 0, indicating no positions are detailed in this particular Form 3 record.

Is Margaret Ekins Smith a 10% owner of ARS Pharmaceuticals (SPRY) according to this Form 3?

According to the Form 3 data, she is not listed as a 10% owner. The reporting person section flags her as an officer (Chief Commercial Officer) but indicates the 10% owner field as 0, meaning she is not reported as a 10% beneficial owner here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/17/2026 - 04:45 PM Accepted by SEC EDGAR 08/17/2026 - 04:44 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Smith Margaret Ekins

(Last) (First) (Middle)

C/O ARS PHARMACEUTICALS, INC.

11682 EL CAMINO REAL, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/17/2026

3. Issuer Name and Ticker or Trading Symbol
ARS Pharmaceuticals, Inc. [ SPRY ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Kathleen Scott, Attorney-in-Fact	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)